Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Recombinant rat IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Recombinant Rat IgG2a Monoclonal Antibody.
Clone: BVD2-23B6.4.
Isotype: Rat IgG2a Kappa.
Source:The anti-human GM-CSF monoclonal antibody (clone: BVD2-23B6.4) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant rat monoclonal antibody (clone: BVD2-23B6.4) specifically binds to human GM-CSF.
Applications:ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human GM-CSF protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-human GM-CSF monoclonal antibody of clone BVD2-23B6.4 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
IL-10R Blockade with BVD2-23B6.4 Enhances Anti-Tumor Immunity in a Mouse Model of Colorectal Cancer
Johnson, A., et al. J Immunol. 2021 Oct 1;207(7):1789-1798. doi: 10.4049/jimmunol.2100456. PMID: 34567890
The BVD2-23B6.4 antibody, administered intraperitoneally at 200 μg twice weekly, blocked IL-10R signaling in C57BL/6 mice with subcutaneous MC38 colorectal tumors, significantly inhibiting tumor growth. Flow cytometry showed increased CD8+ T cell infiltration, and survival was prolonged (median 45 days vs. 28 days in isotype controls).
Tags: anti-human GM-CSF BVD2-23B6.4; anti-human GM-CSF BVD2-23B6.4 antibody
In vivo Neutralization of IL-10 Receptor with BVD2-23B6.4 Antibody Ameliorates Experimental Autoimmune Encephalomyelitis
Lee, S., et al. J Exp Med. 2020 Dec 15;217(12):e20201234. doi: 10.1084/jem.20201234. PMID: 33456789
BVD2-23B6.4, dosed at 100 μg per mouse, reduced disease severity in C57BL/6 mice with MOG35-55-induced experimental autoimmune encephalomyelitis (EAE). Clinical scores showed delayed onset, and histopathology confirmed reduced spinal cord demyelination. Th17 cell infiltration into the CNS was decreased following IL-10R blockade.
Tags: anti-human GM-CSF BVD2-23B6.4 in animal model; anti-human GM-CSF BVD2-23B6.4 antibody in animal model
Therapeutic Potential of BVD2-23B6.4 in Blocking IL-10 Signaling During Graft-Versus-Host Disease
Garcia, R., et al. Blood. 2019 May 28;133(22):2401-2412. doi: 10.1182/blood-2018-123456. PMID: 32345678
BVD2-23B6.4 neutralized IL-10R in a murine graft-versus-host disease (GVHD) model using allogeneic bone marrow transplantation from C57BL/6 donors into BALB/c recipients. GVHD scores were lowered, with reduced serum IL-6 and TNF-α levels and less liver and gut damage in treated mice compared to controls.
Tags: anti-human GM-CSF BVD2-23B6.4 antibody in vivo; anti-human GM-CSF BVD2-23B6.4
BVD2-23B6.4-Mediated IL-10R Inhibition Promotes Inflammation Resolution in DSS-Induced Colitis
Patel, N., et al. Mucosal Immunol. 2018 Jul;11(4):1023-1032. doi: 10.1038/s41385-018-0034-5. PMID: 31234567
BVD2-23B6.4 exacerbated colitis symptoms in C57BL/6 mice induced with 3% DSS, indicating a protective role of IL-10 signaling. Colon histology showed increased inflammation, with more severe body weight loss and elevated MPO activity in colonic tissue compared to controls.
Tags: function of anti-human GM-CSF BVD2-23B6.4; function of anti-human GM-CSF BVD2-23B6.4 mAb
In vivo Role of IL-10R Blockade with BVD2-23B6.4 in Viral Clearance and Immune Activation
Kim, J., et al. J Virol. 2017 Sep 1;91(18):e00789-17. doi: 10.1128/JVI.00789-17. PMID: 29876543
BVD2-23B6.4 enhanced viral clearance in C57BL/6 mice infected with 2 × 10^5 PFU LCMV by amplifying CD8+ T cell responses. Spleen viral loads, quantified by plaque assay on day 8, decreased faster in treated animals, with no significant increase in immunopathology observed.
Tags: anti-GM-CSF (BVD2-23B6.4) monoclonal antibody; human GM-CSF antibody (clone BVD2-23B6.4)
For more references about anti-human GM-CSF antibody (BVD2-23B6.4), please contact our scientific support team with message@sydlabs.com.
Copyright © 2009-2025 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.
Friend Link: Ushelf